Welcome to LookChem.com Sign In|Join Free
  • or
1,2,4-Triazolo[4,3-b]pyridazine, 6-chloro-3-phenyl- is a chemical compound with the molecular formula C9H5ClN4. It is a heterocyclic compound, specifically a triazolo[4,3-b]pyridazine derivative, which features a triazole ring fused to a pyridazine ring. The compound is characterized by the presence of a chloro substituent at the 6-position and a phenyl group at the 3-position. This particular chemical structure may be of interest in medicinal chemistry and drug design due to its potential biological activities and interactions with various molecular targets. However, it is important to note that the specific applications, safety, and environmental impact of 1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE, 6-CHLORO-3-PHENYL- would require further investigation and research.

7190-80-9

Post Buying Request

7190-80-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

7190-80-9 Usage

Heterocyclic compound

Yes
It contains a pyridazine ring fused to a triazole ring, which are both heterocyclic structures.

Pyridazine ring

Present
A six-membered nitrogen-containing ring that is fused to the triazole ring.

Triazole ring

Present
A five-membered nitrogen-containing ring that is fused to the pyridazine ring.

Phenyl group

Substitution at the 6 position
A phenyl group (C6H5) is attached to the 6 position of the pyridazine ring.

Chlorine atom

Substitution at the 6 position
A chlorine atom is attached to the 6 position of the pyridazine ring, in addition to the phenyl group.

Potential pharmacophore

Yes
It has been studied for its potential biological activities, making it a candidate for drug design.

Biological activities

Anticancer and antitumor agent
The compound has been investigated for its potential as an anticancer and antitumor agent.

Field of interest

Medicinal chemistry
Its structure and properties make it a potential candidate for further research and development in the field of medicinal chemistry.

Check Digit Verification of cas no

The CAS Registry Mumber 7190-80-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,1,9 and 0 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 7190-80:
(6*7)+(5*1)+(4*9)+(3*0)+(2*8)+(1*0)=99
99 % 10 = 9
So 7190-80-9 is a valid CAS Registry Number.

7190-80-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 6-chloro-3-phenyl-[1,2,4]triazolo[4,3-b]pyridazine

1.2 Other means of identification

Product number -
Other names 6-Chlor-3-phenyl-1,2,4-triazolo<4,3-b>pyridazin

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:7190-80-9 SDS

7190-80-9Relevant academic research and scientific papers

Synthesis and bioevaluation of 6-chloropyridazin-3-yl hydrazones and 6-chloro-3-substituted-[1,2,4]triazolo[4,3-b]pyridazines as cytotoxic agents

Mamta,Aggarwal, Ranjana,Sadana, Rachna,Ilag, Jeziel,Sumran, Garima

, p. 288 - 295 (2019/02/12)

An efficient synthesis of a series of 6-chloro-3-substituted-[1,2,4]triazolo[4,3-b]pyridazines is described via intramolecular oxidative cyclization of various 6-chloropyridazin-3-yl hydrazones with iodobenzene diacetate. The structures of the newly synth

Electrochemical synthesis of 1,2,4-triazole-fused heterocycles

Ye, Zenghui,Ding, Mingruo,Wu, Yanqi,Li, Yong,Hua, Wenkai,Zhang, Fengzhi

supporting information, p. 1732 - 1737 (2018/04/30)

A reagent-free intramolecular dehydrogenative C-N cross-coupling reaction has been developed under mild electrolytic conditions. In this atom- and step-economical one-pot process, valuable 1,2,4-triazolo[4,3-a]pyridines and related heterocyclic compounds could be synthesized efficiently from commercially available aliphatic or (hetero)aromatic aldehydes and 2-hydrazinopyridines. Various functional groups are compatible with this metal- and oxidant-free protocol which can be carried out on a gram scale easily. This novel method was applied to the synthesis of one of the top-selling drugs Xanax and late stage functionalization for generating chemical diversity in biologically relevant lead molecules.

Synthesis method of 1,2,4-triazolohetercyclic compound

-

Paragraph 0046; 0047, (2018/01/09)

The invention provides a method for synthesizing a 1,2,4-triazolohetercyclic compound. The method comprises the following steps: dissolving a 2-hydrazinohetercyclic compound (I) and an aldehyde compound (II) into acetonitrile A; stirring at 25 DEG C to 80

Synthesis of 1,2,4-Triazolo[4,3-a]pyridines and Related Heterocycles by Sequential Condensation and Iodine-Mediated Oxidative Cyclization

Li, Ertong,Hu, Zhiyuan,Song, Lina,Yu, Wenquan,Chang, Junbiao

, p. 11022 - 11027 (2016/07/27)

A facile and efficient approach to access 1,2,4-triazolo[4,3-a]pyridines and related heterocycles has been accomplished through condensation of readily available aryl hydrazines with corresponding aldehydes followed by iodine-mediated oxidative cyclizatio

Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold

Galatsis, Paul,Henderson, Jaclyn L.,Kormos, Bethany L.,Han, Seungil,Kurumbail, Ravi G.,Wager, Travis T.,Verhoest, Patrick R.,Noell, G. Stephen,Chen, Yi,Needle, Elie,Berger, Zdenek,Steyn, Stefanus J.,Houle, Christopher,Hirst, Warren D.

, p. 4132 - 4140 (2014/09/17)

Leucine rich repeat kinase 2 (LRRK2) has been genetically linked to Parkinson's disease (PD). The most common mutant, G2019S, increases kinase activity, thus LRRK2 kinase inhibitors are potentially useful in the treatment of PD. We herein disclose the str

Triazolopyridazine LRRK2 kinase inhibitors

Franzini, Maurizio,Ye, Xiaocong M.,Adler, Marc,Aubele, Danielle L.,Garofalo, Albert W.,Gauby, Shawn,Goldbach, Erich,Probst, Gary D.,Quinn, Kevin P.,Santiago, Pam,Sham, Hing L.,Tam, Danny,Truong, Anh,Ren, Zhao

, p. 1967 - 1973 (2013/04/24)

Leucine-rich repeat kinase 2 (LRRK2) has been implicated in the pathogenesis of Parkinson's disease (PD). Inhibition of LRRK2 kinase activity is a therapeutic approach that may lead to new treatments for PD. Herein we report the discovery of a series of [

Chemical studies on 3,6-dichloropyridazine (part 2)

El-Salam, N.M. Abd,Al Shoaibi,Ahmed

experimental part, p. 1944 - 1950 (2012/05/31)

3,6-Dichloropyridazine (1) reacted with 2-aminophenol, phenylalanine, acetophenone hydrazone derivatives, acid hydrazide derivatives and amino-aromatic acids (anthranilic acid and 5-bromoanthranilic acid) and yield the compounds (2), (3), (4a,b), (5a,b) a

Palladium-catalyzed coupling of aldehyde-derived hydrazones: Practical synthesis of triazolopyridines and related heterocycles

Thiel, Oliver R.,Achmatowicz, Michal M.,Reichelt, Andreas,Larsen, Robert D.

supporting information; experimental part, p. 8395 - 8398 (2010/12/25)

The palladium-catalyzed intermolecular coupling of aldehyde-derived hydrazones with chloroazines, followed by oxidative cyclization under mild conditions afforded access to a broad variety of bicyclic heterocyclic scaffolds (see scheme) that have potentia

MAOS protocols for the general synthesis and lead optimization of 3,6-disubstituted-[1,2,4]triazolo[4,3-b]pyridazines

Aldrich, Leslie N.,Lebois, Evan P.,Michelle Lewis,Nalywajko, Natalia T.,Niswender, Colleen M.,David Weaver,Jeffrey Conn,Lindsley, Craig W.

scheme or table, p. 212 - 215 (2009/05/07)

General, high-yielding MAOS protocols for the expedient synthesis of functionalized 3,6-disubstituted-[1,2,4]triazolo[4,3-b]pyridazines are described amenable to an iterative analog library synthesis strategy for the lead optimization of an M1 antagonist

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 7190-80-9